IAVI and Moderna Launch Trial of HIV Vaccine Antigens Delivered Through mRNA TechnologyPhase 1 trial aims to build on response seen in proof-of-concept trialCAMBRIDGE, MA and NEW YORK, NY / ACCESSWIRE / January 27, 2022 / IAVI, the nonprofit scientific research organization, and biotechnology company Moderna an.
Human clinical trials have started for an experimental HIV vaccine that uses the same kind of mRNA technology found in Moderna s successful COVID-19 vaccine, the drug company announced this week.